Navigation Links
US and EU Regulatory Submissions for Vandetanib in Advanced Medullary Thyroid Cancer Accepted for Review
Date:9/23/2010

LONDON, Sept. 23 /PRNewswire/ -- AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.

(Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO)

The submissions are supported by the results from the ZETA study evaluating the safety and efficacy of vandetanib compared to placebo in patients with advanced MTC. AstraZeneca is consulting with regulatory authorities on a proposed trade name.

ZETA was a Phase III, double-blind, placebo-controlled study that randomized 331 patients with advanced MTC to oral once-daily vandetanib 300mg or placebo. The study results were presented on 7 June 2010 at the American Society of Clinical Oncology annual meeting in Chicago.  Results from ZETA showed that treatment with vandetanib significantly extended progression-free survival, the primary endpoint of the study, in patients with advanced MTC.  In ZETA, vandetanib demonstrated a 54% reduction in the rate of progression compared to placebo (HR=0.46, p=0.0001). The objective response rate (ORR), a secondary endpoint, was 45% versus 13% across the two groups (p<0.0001).

The most common adverse events (incidence >25%) associated with vandetanib in the ZETA study included diarrhoea, rash, nausea, hypertension and headache. The incidence of protocol-defined QTc prolongation was 8%.  The safety profile of vandetanib in this study was similar to what has been previously observed in other studies in medullary thyroid and non-small cell lung cancer.

Vandetanib targets the vascular endothe
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Advanced Health Media Further Expands Investment in Regulatory Compliance; Company Announces Ms. Susan Y. Leonard as Chief Compliance Officer
2. Spirus Medical Announces Japanese Regulatory Approval to Market ENDO-EASE® Product Line
3. Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online
4. YesDTC Holdings and BioElectronics Receive Japanese Regulatory Review Date
5. BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date
6. Endo Pharmaceuticals Completes Next Step in Regulatory Process for FORTESTA™ for Men With Low Testosterone
7. California Cryobank Welcomes New Director of Quality/Regulatory Affairs
8. Systech International and Videojet Brazil Partner to Meet Brazils Emerging Pharmaceutical Regulatory Requirements
9. Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment
10. Ethicon Endo-Surgery SEDASYS(R) System Receives Regulatory Approval in Canada and CE Mark in European Union
11. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Regen BioPharma, Inc. (OTCBB: RGBP) and ... means of delivering its patented (US Patent 8,263,571) ... utilizing a clinically approved formulation as delivery system.  ... gene silencing therapeutics in which the gene silencing ... body.  By utilizing a local delivery system, potential ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , ... SNY ; EURONEXT: SAN) and the life sciences team ... improve care and outcomes for people with type 1 ... diabetes treatments and devices with Google,s expertise in analytics, ... will explore how to improve diabetes care by developing ...
(Date:8/31/2015)... 31, 2015  Qualcomm Incorporated (NASDAQ: QCOM ... Life, Inc., is collaborating with Davita Healthcare ... solutions powered by Qualcomm Life,s 2net™ Device Connectivity ... continuous care, informed interventions and better management of ... Life,s annual Connect 2015 ecosystem conference ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... (NYSE: CFN ), a leading, global medical ... to sell its OnSite Services instrument management and ... were not disclosed. (Logo:   http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) ... with our strategy to optimize our portfolio of businesses as ...
... 11, 2011 Reportlinker.com announces that a new ... Advanced Drug Delivery Markets (Liposomes, ... http://www.reportlinker.com/p0358466/Advanced-Drug-Delivery-Markets-Liposomes-Polymers-and-Monoclonal-Antibodies.html Drug delivery is evolving ... formulations being discovered frequently. Advanced drug delivery deals ...
Cached Medicine Technology:CareFusion Announces Sale of OnSite Services Instrument Management and Repair Business 2CareFusion Announces Sale of OnSite Services Instrument Management and Repair Business 3Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 2Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 3
(Date:9/1/2015)... OH (PRWEB) , ... September 01, 2015 , ... Mercy ... – has devoted the 10th of its monthly Mercy Health: Helping You Be Well ... affecting one in seven men. , In a concise video on Mercy Health’s ...
(Date:9/1/2015)... ... September 01, 2015 , ... Ogawa’s new massage chairs tout ... more effective and humanlike than ever before. With the goal of bringing wellness to ... the Ogawa Active SuperTrac. , As in its name, the Ogawa Refresh ...
(Date:9/1/2015)... Miramar Beach, FL (PRWEB) , ... September 01, ... ... free pharmacy discount cards, launched its consumer-friendly, informational video this week to coincide ... country: http://www.USAMedicalCard.com/video . , According to the CDC, elementary school children ...
(Date:9/1/2015)... ... September 01, 2015 , ... Éminence Organic ... products, the VitaSkin™ Exfoliating Peels. This revolutionary collection of natural peel solutions complements ... and Clear. , Formulated with alpha hydroxy acids and natural active ingredients, ...
(Date:9/1/2015)... ... September 01, 2015 , ... Dr. Trace Curry successfully placed one of the ... the last month the FDA has approved two intra-gastric balloons, the ORBERA ™ ... the first incisionless, reversible, weight loss procedures available to Americans. , Dr. ...
Breaking Medicine News(10 mins):Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:Ogawa World USA Releases New Massage Chairs to the US 2Health News:Ogawa World USA Releases New Massage Chairs to the US 3Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2
... Queensland research is showing the benefits of resistance training in ... Tim Henwood, a postdoctoral research fellow with UQ and Blue ... over the age of 65 responded to resistance training. ... training can improve muscle strength, power and functional performance." Dr ...
... and ethical issues facing medical physicists are numerous and ... of medicine. Certain activities, such as handling radioactive materials, ... Other activities, such as minimum education and training standards ... , A number of distinguished speakers will help dissect ...
... Focus Through ... Extending the Good Baby Product Line, PLYMOUTH ... BJGP; "BMP Sunstone"; the "Company") today,announced that its wholly-owned ... non-binding letter of,intent to acquire 75 percent of Zhangjiakou ...
... U.S. babies born with hearing loss, experts note , , FRIDAY, ... recommending that all newborns be screened for congenital hearing loss. ... newborn infant,s health care evaluation," U.S. Preventive Services Task Force ... the Colorado Department of Public Health and Environment, said in ...
... Patient Education System that provides hospitals, medical centers and clinics with ... a telephone, pillow speaker, interactive touch screen or computer. , ... ... Systems recently launched several new interface options to it's popular ...
... 17 William F. McMurry, a,Nationally Board Certified ... final Court approval of a settlement in the,first ... Kentucky state court,judge. The settlement gives economic and ... annuities. The Settlement is valued at approximately,$16,400,000., ...
Cached Medicine News:Health News:The benefits of a little resistance for older adults 2Health News:Legal and ethical issues in medical physics 2Health News:Legal and ethical issues in medical physics 3Health News:Legal and ethical issues in medical physics 4Health News:Legal and ethical issues in medical physics 5Health News:Legal and ethical issues in medical physics 6Health News:Legal and ethical issues in medical physics 7Health News:BMP Sunstone Signs Letter of Intent to Acquire Shengda Pharmaceutical Co. 2Health News:BMP Sunstone Signs Letter of Intent to Acquire Shengda Pharmaceutical Co. 3Health News:All Newborns Should Have Ears Screened, Task Force Says 2Health News:Synergy Broadcast Systems Announces Enhancements to MMDS Patient Education System 2Health News:Synergy Broadcast Systems Announces Enhancements to MMDS Patient Education System 3Health News:William F. McMurry - Lead Class Counsel Obtains $16.4 Million Settlement for Elderly Clients 2
High speed, programmable refrigerated centrifuge. High efficiency separations, "Like clockwork" accuracy, aerosol containment, Accommodating, Re-Run control, Glove-Friendly membrane, centrifuge statu...
... 460 family of centrifuges ... that meets a wide ... feature high capacity, versatility ... technology and high safety ...
The Quantum performs centrifugal blood cell separations, urine separations, and sperm cell washing. 24 place angle head, variable speed, and automatic braking system, calibrated variable speed....
... centrifuge is designed especially for ... cover with safety interlock switch, ... emissions, "hold" position for continuous ... motor, maximum stability and compact, ...
Medicine Products: